Adaptimmune Therapeutics (STU:473A) LT-Debt-to-Total-Asset : 0.28 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Adaptimmune Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.28.

Adaptimmune Therapeutics's long-term debt to total assets ratio increased from Dec. 2023 (0.07) to Dec. 2024 (0.28). It may suggest that Adaptimmune Therapeutics is progressively becoming more dependent on debt to grow their business.

Adaptimmune Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Adaptimmune Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics LT-Debt-to-Total-Asset Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.06

0.07

0.28

Adaptimmune Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.07	0.13	0.22	0.28

Adaptimmune Therapeutics LT-Debt-to-Total-Asset Calculation

Adaptimmune Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	66.373	/	234.895
	=	0.28

Adaptimmune Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	66.373	/	234.895
	=	0.28

Adaptimmune Therapeutics (STU:473A) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Adaptimmune Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (STU:473A) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ADAP:USA 473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines